Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1690, Issue 2, 2004, Pages 110-117

  Flintoff, Wayne F ^a   Sadlish, Heather ^a   Gorlick, Richard ^b   Yang, Rui ^b   Williams, Frederick M R ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

(E) GFP; (enhanced) green fluorescent protein; Biotin succinimide, sulfo NHS SS biotin; Biotinylation; Fusion protein; HRP; Methotrexate; Osteosarcomas; Reduced folate carrier; sulfosuccinimidyl 2 (biotinamido) ethyl 1,3 dithiopropionate

Indexed keywords

ALANINE; ASPARAGINE; GLUTAMIC ACID; GLYCINE; GREEN FLUORESCENT PROTEIN; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; METHOTREXATE; PROLINE; REDUCED FOLATE CARRIER; SERINE; THREONINE; TRYPTOPHAN; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL MEMBRANE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TRANSPORT; GENETIC TRANSFECTION; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSPORT KINETICS;

AMINO ACID SEQUENCE; ANIMALS; BIOTIN; BIOTINYLATION; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MEMBRANE; DNA; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; EPITOPES; FOLIC ACID; HUMANS; KINETICS; MEMBRANE TRANSPORT PROTEINS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSFECTION;

CRICETINAE;

EID: 4644251592     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2004.05.008     Document Type: Article

References (31)

1. Meyers P.A., Gorlick R. Osteosarcomas. Pediatr. Clin. N. Am. 44:1997;973-990
2. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., Applewhite A., Vlamis V., Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol. 10:1992;5-15
3. Meyers P.A., Gorlick R., Heller G., Casper E., Lane J., Huvos A.G., Healy J.H. Intensification of preoperative chemotherapy for osteogenic sarcoma: the results of the Memorial Sloan-Kettering (T12) protocol. J. Clin. Oncol. 16:1998;2452-2458
4. Jaffe N., Frei E., Watts H., Traggis D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat. Rep. 62:1978;259-264
5. Seater G., Alvegard T.A., Elomaa I., Stenwig A.E., Holmstrom T., Solheim O.P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma group study. J. Clin. Oncol. 9:1991;1766-1775
6. Bacci G., Ferrari S., Delepine N., Bertoni F., Picci P., Mercuri M., Bacchini P., Brach del Prever A., Tienghi A., Comandone A., Campanacci M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol. 16:1998;658-663
7. Delepine N., Delepine G., Cornille H., Brion F., Arnaud P., Desbois J.C. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res. 15:1995;489-494
8. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., Gorlick R. Mechanisms of methorexate resistance in osteosarcoma. Clin. Cancer Res. 5:1999;621-627
9. Ifergan I., Meller I., Issakov I., Assaraf Y.G. Reduced folate carrier protein expression in osteosarcoma. Cancer. 98:2003;1958-1966
10. Serra M., Reverter-Branchat G., Maurici D., Benini S., Shen J.-N., Chano T., Hattinger C.-M., Manara M.-C., Pasello M., Scotlandi K., Picci P. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann. Oncol. 15:2004;151-160
11. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr. 19:1999;91-122
12. Yang R., Sowers R., Mazza B., Healey J.H., Huvos A., Grier H., Berstein M., Beardsley G.P., Krailo M.D., Devidas M., Bertino J.R., Meyers P.A., Gorlick R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin. Cancer Res. 9:2003;837-844
13. Flintoff W.F., Nagainis C.R. Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and binding. Arch. Biochem. Biophys. 233:1983;433-440
14. Ferguson P.L., Flintoff W.F. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J. Biol. Chem. 274:1999;16269-16278
15. Sadlish H., Murray R.C., Williams F.M.R., Flintoff W.F. Mutations in the reduced folate carrier affect protein localization and stability. Biochem. J. 346:2000;509-516
16. Williams F.M.R., Murray R.C., Underhill T.M., Flintoff W.F. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J. Biol. Chem. 269:1994;5810-5816
17. Underhill T.M., Flintoff W.F. Mutant Chinese hamster ovary cells with defective methotrexate uptake are distinguishable by reversion analysis. Somat. Cell Mol. Genet. 15:1989;49-59
18. Sadlish H., Williams F.M.R., Flintoff W.F. Functional role of Arginine 373 in substrate translocation by the reduced folate carrier. J. Biol. Chem. 277:2002;42105-42112
19. Kaufman Y., Drori S., Cole P.D., Kamen B.A., Sirota J., Ifergan I., Ben Arush M.W., Sahar D., Kaspers G.J.L., Jansen G., Matherly L.H., Rechave G., Toren A., Assaraf Y.G. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer. 100:2004;773-782
20. Zhao R., Assaraf Y.G., Goldman I.D. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol. Chem. 273:1998;7873-7879
21. Flintoff W.F., Williams F.M.R., Sadlish H. The region between transmembrane domains 1 and 2 of the reduced folate carrier forms part of the substrate binding pocket. J. Biol. Chem. 278:2003;40861-40876
22. Cao W., Matherly L.H. Characterization of a cysteine-less human reduced folate carrier: localization of a substrate binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods. Biochem. J. 374:2003;27-36
23. Zhao R., Gao F., Wang P.J., Goldman I.D. Role of the amino acid 45 residue in reduced folate carrier function and ion-transport as characterized by site-directed mutagenesis. Mol. Pharmacol. 57:2000;317-323
24. Drori S., Jansen G., Mauritz R., Peters G.J., Assaraf Y.G. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J. Biol. Chem. 275:2000;30855-30863
25. Gifford A.J., Haber M., Witt T.L., Whetsine J.R., Taub J.W., Matherly L.H., Norris M.D. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia. 16:2002;2379-2387
26. Rosen G., Caparros B., Huvos A.G., Kosloff C., Nirenberg A., Cacavio A., Marcove R.C., Lane J.M., Mehta B., Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 49:1982;1221-1230
27. Williams F.M.R., Flintoff W.F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem. 270:1995;2987-2992
28. Wong S.C., Proefke S.A., Bhushan A., Matherly L.H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J. Biol. Chem. 270:1995;17468-17475
29. Rajgopal A., Sierra E.E., Zhao R., Goldman I.D. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am. J. Physiol., Cell Physiol. 281:2001;C1579-C1586
30. Flintoff W.F., Spindler S.M., Siminovitch L. Genetic characteristics of methotrexate resistant Chinese hamster ovary cells. In Vitro. 12:1976;749-757
31. Worm J., Kirkin A.F., Dzhandhugazyan K.N., Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem. 276:2001;39990-40000